Recent 8-K filings for TWST

• May 4, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Twist Bioscience Q2 revenue $110.7M (+19% YoY); raises FY2026 revenue guidance to $442-447M

  Record revenue $110.7M, 13th consecutive quarter of sequential growth; gross margin 51.6% (+2 pts YoY).

• February 17, 2026, 6:59 PM ET M&A materiality 0.70 neutral item 3.02item 8.01item 9.01

  Twist Bioscience to issue up to 632,328 shares for Invenra license and equity stake

  Total consideration: up to 632,328 TWST shares plus $5M cash.

• February 2, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Twist Bioscience Q1 FY26: Record revenue $103.7M (+17% YoY), raises FY guidance to $435-440M

  Revenue $103.7M (+17% YoY), 12th consecutive sequential growth; exceeded guidance.

• January 12, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Twist Bioscience preliminary Q1 FY2026 revenue ~$103.7M, up 17% YoY, ahead of guidance

  Preliminary Q1 FY2026 revenue ~$103.7M (+/- $0.2M), 17% YoY growth, above guidance of $100-101M.

• November 14, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Twist Bioscience FY2025 revenue $376.6M (+20% YoY); guides for adjusted EBITDA breakeven in Q4 FY2026

  Record FY2025 revenue $376.6M (+20% YoY); Q4 revenue $99.0M (+17% YoY), 11th consecutive sequential growth.

• August 4, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Twist Bioscience reports record Q3 revenue $96.1M (+18% YoY); swings to GAAP net income $20.4M

  Record revenue $96.1M, up 18% YoY; NGS revenue grew 27% to $55.3M.

• May 5, 2025, 7:59 PM ET other material materiality 0.90 positive item 1.01item 2.02item 7.01item 9.01

  Twist reports record Q2 revenue $92.8M; spins out DNA data storage as Atlas with $155M investment

  Record Q2 revenue $92.8M (+23% YoY); gross margin 49.6% vs 41.0%.

• February 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Twist Bioscience Q1 FY2025 revenue $88.7M (+24% YoY), gross margin 48.3%, net loss narrows to $31.6M

  Total revenue $88.7M vs $71.5M YoY; SynBio +28% to $34.4M, NGS +23% to $48.6M.

• November 18, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Twist Bioscience FY2024 rev $313.0M (+28% YoY); Q4 gross margin 45.1%; FY2025 rev guidance $367M-$377M

  FY2024 revenue $313.0M, up 28% vs FY2023; Q4FY24 revenue $84.7M, up 27% YoY, 7th consecutive sequential growth.

• August 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Twist Bioscience Q3 FY2024 revenue $81.5M (+28% YoY); raises FY2024 guidance to ~$310-311M

  Revenue $81.5M, up 28% YoY; gross margin 43.3%, up ~900 bps from 34.4%.

• May 2, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Twist Bioscience reports record Q2 revenue $75.3M (+25% YoY), raises FY2024 guidance

  Record revenue $75.3M (+25% YoY); orders $93.2M (+45% YoY).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

11 positive 0 negative 4 neutral

source · TWST on sec.gov